Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha

World Journal of Urology

Volumn 29, Issue 6, 2011, Pages 779-786

  Juengel, E ^a   Bhasin, M ^b   Libermann, T ^b   Barth, S ^c   Michaelis, M ^a,c   Cinatl Jr , J ^a   Jones, J ^a   Hudak, L ^a   Jonas, D ^a   Blaheta, R A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

^c Blue drugs GmbH   (Germany)

Author keywords

Combination VPA + IFN; Gene expression profiles; HDAC inhibitor VPA; Renal cell carcinoma (RCC)

Indexed keywords

ALPHA INTERFERON; HISTONE DEACETYLASE INHIBITOR; IMMUNOLOGIC FACTOR; VALPROIC ACID;

ARTICLE; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MICROARRAY ANALYSIS; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MICROARRAY ANALYSIS; VALPROIC ACID;

EID: 81855224911     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0582-y     Document Type: Article

References (32)

1. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222.
2. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
3. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Blaheta RA (2009) The Histone Deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 13(8B): 2376-2385.
4. Wedel SA, Mickuckyte A, Juengel E, Jones J, Hudak L, Jonas D, Blaheta RA (2008) Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells. Urologe 47(9): 1175-1181.
5. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Hintereder G, Blaheta RA (2009) Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med 13(8B): 2342-2352.
6. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B, For The French Immunotherapy Intergroup (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110(11): 2468-2477.
7. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1): 289-296.
8. Certa U, Wilhelm-Seiler M, Foser S, Broger C, Neeb M (2003) Expression modes of interferon-α inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-α. Gene 315: 79-86.
9. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW, Cinatl J Jr (2007) Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Canc 96: 1699-1706.
10. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, Rodriguez R (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Canc Res 66: 7237-7244.
11. Kaur S, Sassano A, Joseph AM, Majchrzak-Kita B, Eklund EA, Verma A, Brachmann SM, Fish EN, Platanias LC (2008) Dual regulatory role of phohpatidylinositol 3-kinase in IFN signaling. J Immunol 181(10): 7316-7323.
12. Miles A, Liaskou E, Eksteen B, Lalor PF, Adams DH (2008) CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow. Am J Physiol Gastrointest Liver Physiol 294(5): G1257-G1267.
13. Naschberger E, Croner RS, Merkel S, Dimmler A, Tripal P, Amann KU, Kremmer E, Brueckl WM, Papadopoulos T, Hohenadl C, Hohenberger W, Stürzl M (2008) Angiostatic immune reaction in colorectal carcinoma: impact on survival and perspectives for antiangiogenic therapy. Int J Cancer 123: 2120-2129.
14. Xu QY, Gao Y, Liu Y, Yang WZ, Xu XY (2008) Identification of differential gene expression profiles of radioresistant lung cancer cell lines established by fractionated ionizing radiation in vitro. Chin Med J 121(18): 1830-1837.
15. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM (2007) Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother 30(4): 417-424.
16. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A (2008) Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother 31(3): 313-323.
17. Tanabe K, Campbell SC, Alexander JP, Steinbach F, Edinger MG, Tubbs RR, Novick AC, Klein EA (1997) Molecular regulation of intercellular adhesion molecule 1 (ICAM-1) expression in renal cell carcinoma. Urol Res 25(4): 231-238.
18. Perut F, Cenni E, Unger RE, Kirkpatrick CJ, Giunti A, Baldini N (2009) Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases. Int J Oncol 34(5): 1387-1393.
19. Wu XX, Zeng Y, Jin XH, Kakehi Y (2007) Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes. Oncol Rep 18(2): 353-359.
20. Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A (2004) Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 109(3): 393-401.
21. Jee CD, Kim MA, Jung EJ, Kim J, Kim WH (2009) Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur J Cancer [Epub ahead of print].
22. Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E (2008) UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 7(12): 3780-3788.
23. Li Q, Tang L, Roberts PC, Kraniak JM, Fridman AL, Kulaeva OI, Tehrani OS, Tainsky MA (2008) Interferon regulatory factors IRF5 and IRF7 inhibit growth and induces senescence in immortal Li-Fraumeni fibroblasts. Mol Cancer Res 6(5): 770-784.
24. Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM (2007) Integrins and cancer. Oncology (Williston Park) 21(9): 13-20.
25. Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816-826.
26. Oertl A, Relja B, Makarevic J, Weich E, Höfler S, Jones J, Jonas D, Bratzke H, Baer PC, Blaheta RA (2006) Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int J Mol Med 18: 347-354.
27. Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA (2001) Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumori 87: 173-178.
28. Jones J, Berkhoff S, Weich E, Engl T, Wedel S, Relja B, Jonas D, Blaheta RA (2007) Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes. J Cell Mol Med 11: 826-838.
29. Welser JV, Lange ND, Flintoff-Dye N, Burkin HR, Burkin DJ (2007) Placental defects in alpha7 integrin null mice. Placenta 28: 1219-1228.
30. Welser JV, Lange N, Singer CA, Elorza M, Scowen P, Keef KD, Gerthoffer WT, Burkin DJ (2007) Loss of the α7 integrin promotes extracellular signal-regulated kinase activation and altered vascular remodeling. Circ Res 101(7): 672-681.
31. Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN, Nelson J, Michalopoulos GK, Luo JH (2007) Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 99(11): 868-880.
32. Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC (2007) Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 67: 1832-1841.